Fortress Biotech (NASDAQ:FBIO – Get Rating) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10, Fidelity Earnings reports. Fortress Biotech had a negative net margin of 94.06% and a negative return on equity of 27.80%. During the same quarter last year, the company earned ($0.11) earnings per share.
Shares of FBIO traded up $0.06 during mid-day trading on Friday, hitting $0.86. 695,679 shares of the company traded hands, compared to its average volume of 683,029. Fortress Biotech has a 1-year low of $0.79 and a 1-year high of $4.49. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.33 and a current ratio of 3.43. The business has a 50 day moving average of $1.21 and a 200 day moving average of $2.04.
FBIO has been the subject of a number of research reports. Roth Capital reaffirmed a “buy” rating on shares of Fortress Biotech in a research note on Tuesday, March 29th. Zacks Investment Research raised shares of Fortress Biotech from a “strong sell” rating to a “hold” rating in a research note on Friday. StockNews.com lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, TheStreet lowered shares of Fortress Biotech from a “c-” rating to a “d+” rating in a research report on Monday, February 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.38.
Fortress Biotech Company Profile (Get Rating)
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.
- Get a free copy of the StockNews.com research report on Fortress Biotech (FBIO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.